Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Cigna $3.5 billion senior notes offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of $1…
Kala Pharmaceuticals $126.2 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with…
McKesson splits off interest in Change Healthcare
Davis Polk advised McKesson Corporation in connection with the offer by McKesson to exchange shares of McKesson common stock…
NanoString Technologies $230 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NanoString Technologies, Inc. of …
Millendo Therapeutics amendments of at-the-market offering program
Davis Polk advised the sales agents in connection with certain amendments of the SEC-registered at-the-market offering…
J M Smith sale of smith Technologies to Francisco Partners
Davis Polk is advising J M Smith Corporation in connection with the sale of its technologies division, Smith Technologies,…
NuVasive $450 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. of $450 million…
Atara Biotherapeutics $100 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atara Biotherapeutics, Inc. of its common…
CytomX Therapeutics $75 million at-the-market offering
Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by CytomX Therapeutics, Inc…
BioXcel Therapeutics $73.6 million stock offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300…